ArticleDermatology and therapy2026
Efficacy and Safety of Benvitimod Compared with Halometasone in Patients with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionTopical corticosteroids are regarded as the first-line therapy for chronic hand eczema (CHE), despite a lack of substantial evidence from randomized controlled trials to confirm their efficacy. Topical benvitimod is a potential alternative for long-term maintenance.
methodsA prospective, single-center, open-label randomized trial was conducted, using a parallel-group design and enrolling 64 patients who had moderate-to-severe CHE. Patients were randomly divided into two treatment groups: 32 patients used 1% benvitimod cream twice a day for 8 weeks, whereas the other 32 patients received halometasone cream on the same application schedule and duration. The percentage of patients who achieved "treatment success" at week 12 was the primary endpoint. Secondary endpoints included changes in physician-assessed Hand Eczema Severity Index (HECSI), patient-reported subjective scores, the relapse rate, and adverse events. Patient-reported subjective scores included Patient Global Assessment (PaGA), Dermatology Life Quality Index (DLQI), and Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
resultsFifty-nine patients completed the trial (30 in the benvitimod group and 29 in the halometasone group). The treatment success rate was 26.7% (8/30) in the benvitimod group and 24.1% (7/29) in the halometasone group (p = 0.824) at week 12. From baseline to week 12, the two groups demonstrated significant reductions in HECSI, PaGA, DLQI, and QOLHEQ scores (p < 0.05). However, no statistically significant differences were observed between the two groups. Among patients who achieved treatment success, 25.0% (2/8) patients in the benvitimod group and 57.1% (4/7) patients in the halometasone group relapsed at week 24 (p = 0.315). The main adverse events associated with benvitimod were skin pigmentation, pruritus, and skin dryness, none of which led to treatment discontinuation.
conclusionsBenvitimod exhibits efficacy comparable to halometasone in managing moderate-to-severe CHE, along with a favorable safety and a low relapse rate. TRIAL REGISTRATION NUMBER: ChiCTR2100051948.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.